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Abstract
Obesity, a significant risk factor for various chronic diseases, is universally related to dyslipidemia mainly
represented by decreasing high-density lipoprotein cholesterol (HDL-C), which plays an indispensible role in
development of cardiovascular disease (CVD). However, the mechanisms underlying obesity and low HDL-C have
not been fully elucidated. Previous studies have focused on the alteration of HDL catabolism in circulation
following elevated triglyceride (TG). But recent findings suggested that liver and fat tissue played pivotal role in
obesity related low HDL-C. Some new molecular pathways like microRNA have also been proposed in the
regulation of HDL metabolism in obesity. This article will review recent advances in understanding of the potential
mechanism of low HDL-C in obesity.
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Introduction
Following the change of dietary structure and the limita-
tion of physical activity, the increasing prevalence of
obesity is becoming a serious threat to global public
health. Obesity is associated with various chronic dis-
eases, particularly cardiovascular diseases (CVD), dia-
betes mellitus type 2, sleep apnea, certain types of
cancer and osteoarthritis [1]. In humans, one of the
characteristics of obesity is dyslipidemia which includes
high levels of triglycerides (TG) in very-low-density lipo-
proteins (VLDL) and low levels of high-density lipopro-
tein cholesterol (HDL-C) [2]. Actually, dyslipidemia is a
more valuable predictor for the development of CVD
compared to other manifestations of obesity. Findings of
the Emerging Risk Factors Collaboration’s study demon-
strated that assessments of body size could not compen-
sate for the lack of blood lipids assay, particularly the
information about total cholesterol and HDL-C [3]. It is
widely known that low plasma HDL-C levels are inver-
sely related to the risk of CVD and independent of
other risk factors [4,5]. In addition, under the state of
obesity, HDL particles can be modified to generate dys-
functional HDL which is indicated as a more important
risk factor for CVD [6]. The degeneration of HDL that
typically accompanies obesity is therefore of consider-
able importance, whereas the mechanisms underlying
obesity and HDL alteration have not been fully eluci-
dated. In this review, we are going to introduce the
changes of HDL metabolism in obese individuals and
focus on the new insights of the potential mechanism.
Obesity-related changes in HDL metabolism
Metabolism and function of HDL
HDL plays a critical role in cholesterol homeostasis. It
mediates the transfer of cholesterol from extra hepatic
tissues to the liver. This process of reverse cholesterol
transport (RCT) is generally thought to be the central
antiatherogenic effect of HDL [7]. There are several
steps involved in the RCT. To begin with, lipid-poor
apoA-I (the major apolipoprotein of HDL) is secreted
from the liver or intestine and released into the plasma
for circulation to peripheral cells, where it removes
excess cholesterol, forming nascent HDL. In the first
step of RCT, a specific cell membrane protein, ATP-
binding cassette transporter A1 (ABCA1) plays a key
role in cellular cholesterol efflux [8]. The ABCA1 shut-
tles back and forth, transferring cholesterol from lipid
pool to apoA-I. Then the free cholesterol on HDL sur-
face is esterified by lecithin cholesterol acyl transferase
(LCAT) [9]. Next, the cholesterol esters move to the
HDL core, forming the more spherical mature HDL3.
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through ATP-binding cassette transporter G1 (ABCG1)
and scavenger receptor class B type I (SR-BI) [10]. As
the HDL3 gets more cholesterol, it expands to HDL2.
Now rich in cholesteryl ester (CE), HDL2 engages in the
exchange with TG-rich lipoproteins mediated by choles-
teryl ester transfer protein (CETP) [11]. The remaining
HDL2 returns to the liver, interacting with SR-BI recep-
tor which removes cholesterol and converts HDL2 to
HDL3. Liver cholesterol can then be reutilized in VLDL
assembly or transformed into bile acids [12]. Through
RCT process, peripheral tissues, like vessel-wall macro-
phages, remove their excess cholesterol, thus preventing
cholesterol accumulation and atherosclerotic plaque for-
mation. Furthermore, HDL also exerts other antiathero-
genic and vascular protective functions such as
antioxidative, antithrombotic and anti-inflammatory
actions [7]. Epidemiologic studies have shown that there
was an inverse correlation between HDL-C levels and
the risk of CVD. For a 5 mg/dl decrement in HDL-C
between individuals, there was a 14% incremental risk of
cardiovascular events [13]. Each 1 mg/dl increase in
HDL-C is associated with a 2%-3% reduction in the risk
of CVD [14]. As a result, HDL-raising therapies are con-
sidered to be a promising way to reduce the morbidity
of CVD. However, a number of factors have been shown
to contribute to the reduction of HDL-C. In particular,
obesity is the most frequent cause of low concentration
of HDL-C and HDL dysfunction.
Obesity affects the quantity of HDL
There are a great number of evidences that the concen-
trations of HDL-C are adversely altered in obese people,
especially in the case of metabolic syndrome. Obesity is
the fundamental manifestation of metabolic syndrome
which also includes insulin resistance, hypertriglyceride-
mia, reduced HDL-C level, elevated blood pressure and
glucose intolerance. Metabolic syndrome is highly preva-
lent. Datas from the Third National Health and Nutri-
tion Examination Survey showed that the age-adjusted
prevalence of metabolic syndrome was 23.7% [15]. The
most common component of the metabolic syndrome
was obesity (39%) followed immediately by the low
HDL-C levels (37%) [16].
Generally speaking, HDL-C levels are associated with
both the degree and distribution of obesity. Lipid
Research Clinics Program Prevalence Study for 6865
white people suggested that the Quetelet index of body
mass was significantly and inversely associated with
plasma HDL-C in children and adults of both sexes.
The relationship between body mass and HDL-C was
independent of smoking, alcohol intake, exogenous
estrogen hormone use, and TG levels [17]. In the third
examination cycle of the Framingham Offspring Study
for 1566 men and 1627 women, BMI was inversely and
linearly associated with HDL-C concentration. As the
BMI increased, there was a steady increase in age-
adjusted levels of TG and a decline in HDL-C [18]. Spe-
cifically, the correlation of low HDL-C with obesity
seems to be strongest with central obesity which is char-
acterized by intra-abdominal or visceral fat deposition.
Compared to mid-thigh fat, intra-abdominal fat was a
more critical independent predictor for low HDL2 levels
in obese premenopausal women [19]. The level of HDL-
C was inversely correlated with abdominal circumfer-
ence which directly represents the degree of central obe-
sity and better predicts of low HDL-C levels [20].
Increasing intra-abdominal fat area, quantified by com-
puted tomography scan, was an important determinant
of decreased HDL-C [21].
Obesity affects the quality of HDL
Obesity not only affects the concentration of HDL-C in
plasma, but also has an influence on the functionality of
HDL. Emerging evidence indicates that HDL can lose its
protective activity and even become atherogenic under
certain conditions. The dysfunctional of HDL have been
shown to be associated with complications of obesity,
such as infection, inflammation, diabetes and CVD [22].
Compared to normal HDL, HDL from patients in an
acute phase reaction did not inhibit monocyte chemo-
taxis but actually increased it [23], demonstrating the
anti-inflammatory function is impaired. Furthermore,
The anti-oxidant function of HDL cholesterol is signifi-
cantly altered in obese patients compared with healthy
controls and HDL isolated from type 2 diabetic patients
has displayed low endothelial protective activities [24].
Sasahara et al [25] studied the pathway of cholesterol
efflux from fibroblasts by testing plasma samples from
obese and lean subjects. Compared to lean individuals,
the overall capacity of HDL to promote cholesterol
efflux is reduced in obese ones. Considering cholesterol
efflux capacity, independently of the HDL-C level, is the
main metric of HDL function and has a strong inverse
association with coronary artery disease [26], the
impaired cholesterol efflux capacity may have a more
crucial impact on the development of CVD in obese
individuals.
Even though it is undeniable that obesity influences
the metablism of HDL, there are some disputes on the
explanations for that phenomenon. Up to now, several
kinetics studies put forward some hypothesis that factors
both intrinsic to HDL particles and extrinsic to HDL
particles were involved in obesity related HDL-C reduc-
tion. One hand, the overproduction of free fatty acid
(FFA) and VLDL is regarded as the initiator of HDL-C
reduction [27]. On the other hand, some key enzymes
involved in HDL metabolism, such as CETP, LCAT,
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protein(PLTP), are changed in obese people with insulin
resistance, promoting this process [28]. What’sm o r e ,
the increased plasma clearance of apoA-I and downre-
gulation of its production also offer some contributions
to the reduction of HDL-C [29]. In spite of these inter-
pretations, there is no consolidated explanation for the
association between obesity and decreased HDL-C
levels. In the following part, we will review several
recent findings that provide new clues to help us under-
stand the potential mechanism underlying obesity and
HDL degeneration.
Changes in HDL component
HDL clearance accelerates when it gets fat
HDL-C level reflects the balance between the rate of
HDL clearance and the rate of HDL production. How-
ever, studies have demonstrated that increased clearance
of HDL undertook more responsibilities for HDL
decrease in obese individuals [30]. And further studies
showed the compositional changes in HDL, especially
triglyceride enrichment, accounted for the majority of
causes of its clearance enhancement. Under the states of
obesity and insulin resistance, adipose tissue releases
more free fatty acids (FFAs), the substrate for VLDL for-
mation in liver, to circulation. The elevated VLDL levels
in plasma will lead more TG in VLDL to be transferred
to HDL through the act of CETP [31]. Moreover, CETP
activity increases significantly in obese subjects [32]. As
a result, a greater number of HDL particles are choles-
terol depleted and TG enriched. Hepatic lipase (HL),
which is also increased in obesity [33], hydrolyzes TG-
rich HDL, releasing lipid-poor apoA-I and forming rem-
nant HDL particles(a-migrating, lipolytically modified
HDLs) [34]. Lipid-poor apoA-I can be recycled to form
nascent HDL particles, but more likely to be cleared by
kidney. On the other hand, HDL remnants bind to liver
or kidney that mediates the remnants uptake, internali-
zation, and degradation.
However, there is no agreed opinion concerning the
mechanisms of enhanced HDL remnant clearance. One
explanation proposed by Xiao et al [35] demonstrated
that compared to native and TG-rich HDL, the binding
of remnant HDL was markedly higher in both HepG2
cells and HEK293 cells. Remnant HDL was internalized
to a greater extent in both cell types and was more
readily degraded in HEK293 cells. The authors also
demonstrated that the increased binding of HDL rem-
nant was not mediated by the low-density lipoprotein
receptor (LDLR) or SR-BI. In addition, Brown et al [36]
suggested that endothelial lipase (EL), which is also ele-
v a t e di no b e s i t ya n di n s u l i nr e sistance [37], hydrolyzed
phospholipids from remnant HDL particles and further
enhanced their catabolism. However, the molecular
pathways of uptake and degradation of HDL remnants
require further studies.
And so far, there is still no knowing if the TG-rich
HDL (before or after hydrolysis by HL) has decreased
function of cholesterol efflux and RCT. Previous study
has shown that in obese individuals, the conversion of
pre-b1t op r e - b2 HDL was inhibited [38]. The pre-b1
HDL (similar to nascent HDL) is initial mediator of cho-
lesterol efflux from peripheral cells. But the increase of
pre-b1 HDL in obesity did not result in enhancement of
transfer of cholesterol from peripheral cells to HDL sub-
fractions. On the contrary, the peripheral cholesterol
transfer to HDL subfractions was impaired in obesity.
These results suggest that the changes in HDL compo-
nents would have some effects on its functions.
Prevent HDL from getting fat
As mentioned above, in the process of triglycerides
transferring from VLDL to HDL, CETP plays an indis-
pensable role, especially in obese and insulin resistant
states. Humans genetically deficient in CETP had mark-
edly elevated HDL-C [39]. Animal experiments revealed
that inhibitions of CETP blocked the exchange of TG
and cholesterol, thus prevented HDL from getting fat
and effectively raised HDL-C levels [40]. Hence, inhibi-
tion of CETP with CETP inhibitors, such as torcetrapib,
was believed to be beneficial for HDL-C metabolism
and finally prevent cardiovascular events [41]. Unfortu-
nately, the large clinical trial ILLUMINATE was stopped
prematurely as a result of an excess of deaths and mor-
bidity in the group receiving torcetrapib and atorvastatin
compared to atorvastatin alone [42]. However, further
studies suggested that the HDL from patients treated
with torcetrapib was functional and promoted regression
of atherosclerosis and the failure may have been caused
by off-target toxicity of torcetrapib [42]. Despite the fail-
ure of torcetrapib, inhibition of CETP still seems to be a
sound strategy for increasing HDL-C. Recent clinical
trial has demonstrated that anacetrapib (another CETP
inhibitor) had robust impact on LDL and HDL choles-
terol and did not result in the adverse effects observed
with torcetrapib [43].
Besides CETP, the factors that associated with hyper-
triglyceridemia are also potential targets of preventing
the changes in HDL component for the reason that
hypertriglyceridemia is an initial requirement for the
overproduction of TG-rich HDL. Chan et al [44] showed
that elevated plasma apoC-III was a predictor of hyper-
catabolism of HDL and apoA-I. By inhibiting lipoprotein
lipase and hepatic uptake, apoC-III can impair the
hydrolysis of TG [45]. The elevated level of apoC-III in
plasma, which was associated with insulin resistance,
will promote the formation of TG-rich HDL. Moreover,
adipose fatty acid binding protein 4 (FABP4) which is
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tion with TG-rich VLDL and inverse correlation with
HDL-C. And these correlations are not affected by age,
gender, BMI or other factors, indicating that FABP4
may directly modulate HDL-C metabolism [46]. Other
researches found that the accumulation of fat in liver
obviously increased the production of TG-rich
HDL [47,48]. Although further studies are still needed,
reducing the levels of apoC-III, FABP4 and liver fat
would prevent the changes in HDL component and help
to ameliorate HDL-C metabolism, especially in obesity
and insulin resistance [49].
Effect of hypertrophied adipocyte on HDL
Efflux of cholesterol from hypertrophied adipocyte
decreases
A d i p o s et i s s u ei st h eb i g g e s tt i s s u ei nb o d yw h i c hc a n
store large amounts of lipids, and therefore it is poten-
tially a reservoir of cholesterol. Thus the impact of adi-
pose tissue on HDL metabolism is possible immense,
especially in obesity. Adipocytes are the predominant
cells in adipose tissue and their main function is to
store excess energy as the form of TG. Additionally, adi-
pose tissue is also recognized as an endocrine organ
because adipocytes have the ability to secrete a large
number of cytokine which named as adipokines, such as
leptin, adiponectin, tumor necrosis factor-a (TNF-a)
and interleukin-1b (IL-1b) [50]. In obesity, abnormal
excess energy leads to adipocytes obviously enlarge and
the hypertrophied adipocytes manifest several altered
metabolic properties that play a key part in the obesity
related dyslipidemia.
As previously mentioned, cholesterol efflux to HDL,
especially from macrophage, is the main antiatherogenic
effect of HDL. However, the cholesterol efflux from
macrophage and its expression of ABCA1 has minimal
contribution to plasma HDL-C levels [51]. In contrast,
adipose tissue contains the largest pool of free choles-
terol and in obese adults it contains over 50% of the
total body cholesterol [52,53]. Hence, for obese indivi-
duals, cholesterol efflux from this peripheral tissue may
play a relatively important role in modulation of the
whole circulating HDL-C levels. A research group
injected 3T3-L1 adipocytes which labeled with
3H-cho-
lesterol into the bodies of mice and tracked movement
of label onto plasma HDL [54]. The authors demon-
strated that adipocytes supported transfer of cholesterol
to HDL in vivo as well as in vitro and provided evidence
that adipocyte cholesterol efflux was controlled by
ABCA1 and SR-BI, but not ABCG1. Furthermore, TNF-
a, an inflammatory factor, reduced both ABCA1 and
SR-BI expression and impaired cholesterol efflux from
adipocytes. These results indicated that adipocyte
inflammation impaired its cholesterol efflux to HDL.
Thus, as adipose inflammation is a hallmark of obesity
and insulin resistance [50], loss of adipocyte cholesterol
efflux to HDL may directly contribute to low HDL-C
levels related to obesity.
Another group found that activation of the lipolysis of
3T3-L1 adipocytes promoted a 22% increase in choles-
terol efflux to HDL particles [55]. However, the
enhancement of cholesterol efflux was not due to the
levels of ABCA1 and SR-BI. Brefeldin A-sensitive vesicu-
lar transport contributed to the major part in the
enhancement of cholesterol efflux associated with adipo-
cytes lipolysis. In consistent with this, sustained weight
loss through dieting or exercise which leads to fat mobi-
lization of adipocytes could reverse the decrease of
HDL-C levels in obesity [56,57].
Influx of cholesterol into hypertrophied adipocyte
increases
Although adipose tissue contains large amounts of cho-
lesterol, the capacity of cholesterol synthesis of adipo-
cytes is extremely limited [58]. The cholesterol
accumulation of adipose tissue is dependent on the
influx of cholesterol. Adipocytes can selectively uptake
CE from HDL through both SR-BI dependent and SR-BI
independent pathways [59]. In both of the uptake path-
ways, the CE cargo of HDL is selectively unloaded into
cells without internalization and degradation of the
entire lipoprotein [60]. However, several researches
observed that with the increased uptake of CE form
HDL, plasma HDL-C levels were rapidly reduced [61,62].
Our recent experiments have shown that the adipose
tissue from greater omentum of human retained a large
amount of apoA-I (unpublished data). Hence, we specu-
lated that the increased cholesterol influx into adipo-
cytes is accompanied by the internalization of apoAI as
no de novo synthesis of apoAI in adipocyte was noted.
Adipokines affect HDL metabolism
In the state of obesity, the secretion of adipokines is also
altered. Nearly all of the adipokines are increased in
obesity except for adiponectin. Adiponectin (APN) is a
peptide mainly synthesized in adipose tissue and plays
an important role in modulating glucose metabolism
and inhibiting atherosclerosis [63]. A great number of
studies have shown that APN levels were reduced in
individuals with obesity and that weight loss could
increase APN levels [64,65]. As an antiatherogenic adi-
pokine, APN has critical influence on HDL metabolism.
Human studies have found that plasma APN concentra-
tions were positively correlated with HDL-C levels and
the relationship is independent of BMI, body fat distri-
bution and insulin sensitivity [66,67]. Verges et al veri-
fied that APN was a critical determinant of apoA-I
catabolism. There was a significant negative correlation
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metabolic syndrome and normal subjects [68]. In vitro
experiments demonstratedt h a tA P Ne n h a n c e dm R N A
expression and protein secretion of apoA-I from HepG2
cells [69]. Furthermore, APN could upregulate ABCA1
at both mRNA and protein levels in HepG2 cells, sug-
gesting that APN might increase HDL assembly through
enhancing ABCA1 pathway and apoA-1 synthesis in the
liver. In consistent with that, the apoA-I protein levels
and ABCA1 expression in liver were reduced in APN-
knockout mice compared with wild-type mice [70].
What’s more, APN could reduce the release of ApoB
and ApoE from hepatocytes, resulting in reduced release
of TG-rich lipoproteins from the liver thus preventing
the formation of TG-rich HDL and leading to elevated
systemic HDL-C [71].
In obese individuals, the inflammatory cytokines which
released from hypertrophied adipocytes are raised and
may be directly associated with the reduction of HDL-C
and CVD development. The pro-inflammatory state is a
main feature of obesity. In other inflammatory states
such as rheumatoid arthritis or acute infections, plasma
HDL-C levels are also obviously reduced [72,73]. TNF-a
and IL-1b, as universal inflammatory cytokines, have
been identified to downregulate apoA-I gene expression
in hepatocytes with a dose-dependent manner [74].
Further studies revealed that TNF-a suppressed apoA-I
promoter activity through both the MEK/ERK and JNK
pathways [75].
Besides adipocytes, adipose tissue macrophage content
(ATMc) is also associated with increasing adiposity.
Moreover, ATMc is another determinant for lower
HDL-C level independent of BMI [24]. This suggests
that ATMc also have influence on the HDL metabolism.
In addition, in vivo experiments provided evidence that
inflammation impaired RCT at multiple steps in its
pathway. Impairment of RCT and HDL efflux function,
independent of HDL-C levels, may contribute to athero-
sclerosis in chronic inflammatory states including obe-
sity and diabetes [76]. In vitro experiments displayed
similar results that inflammatory cytokines down regu-
lated the expression of ABCA1 and ABCG1 in mouse
macrophages [77], thus blocked cholesterol efflux from
macrophages and promoted atherosclerosis formation.
(Figure 1).
Effect of hepatocytes on HDL
Hepatic ABCA1 is key to circulating HDL-C
Liver is the centric organ for lipid metabolism including
LDL, TG, and HDL. Although hepatic apoA-I is the
major protein source of HDL, hepatic ABCA1 seems
indispensable to the production of circulating HDL.
Animal study has revealed that overexpression of adeno-
virally delivered ABCA1 in the liver of mice resulted in
significant increase in plasma HDL-C [78]. Similarly,
transgenic mice overexpressing ABCA1 in the liver
showed prominent elevation of plasma HDL-C [79]. On
the other hand, 80% decrease in plasma HDL-C was
observed in mice with liver-specific deletion of
ABCA1 [80]. These studies suggested that hepatic
ABCA1 is critical in maintaining the circulating HDL-C
levels by formation of nascent HDL particles [81].
Although extrahepatic ABCA1 is essential for the
maturation of HDL particles, it contributes little to the
plasma HDL-C levels [82,83]. However, the regulation
of hepatic ABCA1 in obesity and insulin resistance has
not yet been clearly defined.
Hepatic miR-33 as novel regulatory pathway of HDL-C
In the search of the regulatory factors of intracellular
cholesterol homeostasis, two independent groups have
concurrently discovered a novel pathway——microRNA-
33a(miR-33a) and its host gene SERBP-2 [84,85].
SREBP-2(sterol regulatory element-binding protein-2)
has been recognized as an important sensor of intracel-
lular cholesterol. It can control hepatic cholesterol
Figure 1 Effect of adipocyte on HDL. Hypertrophied adipocytes
manifest several altered metabolic properties that play a role in
lowered HDL-C. Adipocyte inflammation impairs its cholesterol
efflux to HDL while cholesterol influx to adipocyte is increased in
the state of obesity. In addition, altered adipokines downregulate
apoA-I and ABCA1 gene expression in hepatocytes, thus reduce
HDL assembly in the liver. ABCA1, ATP-binding cassette transporter
A1; SR-BI, scavenger receptor type-BI; APN, adiponectin; TNF-a,
tumor necrosis factor-a; IL-1b, interleukin-b; ATMc, adipose tissue
macrophage content; apoA-I, apolipoprotein AI; HDL-C, high-density
lipoprotein cholesterol.
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HMG-CoA reductase and cholesterol uptake via LDL-
receptor. MiR-33a is located in the intron of SREBP-2
gene and appears to be co-regulated with the SREBP-2
by cellular cholesterol content.
MiR-33a was identified to target ABCA1, resulting in
ABCA1 silencing through post-transcriptional repres-
sion. As a consequence of this targeting, miR-33a lim-
ited the efflux of cholesterol to apoA-I in both
macrophages and hepatocytes. Overexpression of miR-
33 in mice resulted in significantly reduced hepatic
ABCA1 expression as well as a progressive decline of
plasma HDL-C. Conversely, mice expressing anti-miR-
33 showed a 50% increase in hepatic ABCA1 protein
and a concomitant 25% increase in plasma HDL-C
levels [84]. Horie et al [86] generated miR-33-deficient
mice and revealed that genetic deletion of miR-33
resulted in increased hepatic ABCA1 expression and ele-
vated apoA-I dependent cholesterol efflux. Moreover,
miR-33-deficient mice had significant higher serum
HDL-C levels than WT mice (25%). Rayner et al [87]
studied the impact of miR-33 inhibition in mice defi-
cient for LDL receptor (Ldlr
-/- mice), with established
atherosclerotic plaques. Ldlr
-/- mice treated with anti-
miR-33 showed an increase in plasma HDL-C levels and
a reduction in plaque size with an increase in plaque
stability. These studies suggest that raising HDL-C levels
by anti-miR-33 treatment promotes atherosclerosis
regression and holds tremendous potential for the pre-
vention and treatment of CVD.
Notably, in addition to the cholesterol transport genes,
miR-33 also inhibits translation of several transcripts
encoding proteins involved in fatty acid b-oxidation,
including CPT1A(carnitine palmitoyltransferase 1A),
CROT(carnitine O-octanoyltransferase) and HADHB(b-
subunit of the mitochondrial trifunctional protein) [88].
Each of them plays a indispensable role in the fatty acid
oxidation pathway. Thereby, overexpression of miR-33a
led to reduced fatty acid degradation and lipid accumu-
lation in liver. Thus, the transcript encoding SREBP-2
and miR-33a contains a protein that increase lipid
synthesis and a microRNA that prevent export and
degradation of newly synthesized lipids.
Hepatic miR-33b and SREBP-1c may coordinate the HDL-C
and TG variation in obesity
Besides miR-33a, another member of the miR-33 family,
miR-33b, is found within the intron of human SREBP-
1c gene. There are only two nucleotides difference
between miR-33a and miR-33b. However, the two-
nucleotide variation does not appreciably affect the gene
targeting by these miRNAs [89]. As for the host gene
SREBP-1c, it is the predominate isoform of SREBPs in
the liver and preferentially enhances transcription of the
genes involved in fatty acid synthesis but not cholesterol
synthesis [90]. In addition, the transcriptional regulation
of the SREBP-1c is complex and is of great importance
for the metabolism homeostasis of fatty acid. Insulin
was shown to be a key regulator of SREBP-1c gene
expression [91,92]. Insulin selectively stimulates SREBP-
1c transcription in liver and elevated SREBP-1c in turn
mediates insulin-stimulated fatty acid synthesis. Further
researches revealed that the alternation of adipokines
also had impacts on SREBP-1c expression. TNF-a could
induce hepatic SREBP-1c expression [93] and adiponec-
tin could suppress hepatic SREBP-1c expression [94].
As we know, obesity has a strong association with insulin
resistance, hyperinsulinemia and disorders of adipokines. In
consistent with that, upregulation of SREBP-1c in liver was
observed in both obese patients [95,96] and mouse models
[97]. As mentioned above, miR-33b is encoded in human
SREBP-1c gene. Furthermore, increased expression of miR-
33b was observed when activating SREBP-1 with an LXR
agonist [89]. It is reasonable to deduce that the expression
of miR-33b in liver would be activated in obesity with the
upregulation of SREBP-1c gene.
Additionally, our primary data showed that compared
to the solo-cultured hepatocytes, hepatic cells co-cul-
tured with adipocytes presented increased expression of
SREBP-1c while decreased expression of ABCA1. This
indicated that the paracrine of adipocytes had effects on
hepatic lipid metabolism, both on TG and HDL. How-
ever, the specific links between liver and adipose tissue
have not yet been identified. According to the
researches we mentioned above, we propose that in the
state of obesity, hyperinsulinemia and disorders of adi-
pokines would induce the expression of hepatic SREBP-
1c gene as well as miR-33b. The upregulation of
SREBP-1c would activate its downstream genes, such as
fatty acid synthetase (FAS) and acetyl-CoA carboxylase
(ACC) and accelerate TG and VLDL synthesis. At the
same time, upregulation of miR-33b would repress
hepatic HDL assembly through the inhibition of ABCA1
and promote fat accumulation through the repression of
fatty acid degradation. Thus, elevated plasma TG level
and reduced HDL-C level would be manifested simulta-
neously in obese individuals (Figure 2).
Interestingly, although miR-33a is highly conserved in
mammals, miR-33b is different between humans and
mice. SREBP-1c gene in human encodes miR-33b, but
there is no miR-33b in mice. This is consistent with the
fact that obese and insulin-resistant mouse models man-
ifest all of the human features of metabolic disorders
except a reduction in HDL-C. Conversely, in obese
mice, the high level of cholesterol would suppress
SREBP-2 and miR-33a expression. This is consistent
with the observation that dietary fat induced obesity
slightly increases HDL-C levels in mice [98].
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As a conclusion, low level of HDL-C is a common
lipid disorder in obese people and plays an indispensi-
ble role in the development of CVD. Both the factors
intrinsic to HDL particles and extrinsic to HDL parti-
cles are involved in the abnormal HDL metabolism in
obesity. In obese individuals, the changes in HDL com-
ponent play a major role in its rapid clearance. Both
cholesterol efflux and influx of adipocytes may affect
plasma HDL-C levels. And the alternations of adipo-
kines in obesity also contributed to low HDL-C. In
addition, we propose that hepatic miR-33b and its host
gene SREBP-1c coordinate HDL-C and TG variations.
These new findings provide new clues to the under-
standing of the potential mechanism of low HDL-C in
obesity and potential targets for preventing and treat-
ing HDL-C reduction.
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